CoChat

Considerations in the Development of Drugs to Treat Sarcopenia

Brass, Eric P., Sietsema, Kathy E. · 2011 · Journal of the American Geriatrics Society
Cited by 31

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Sarcopenia describes reduced skeletal muscle mass and impaired muscle function associated with aging and with a variety of chronic diseases prevalent in the aging population. With increasing understanding of the molecular pathways participating in the structural and functional changes affecting skeletal muscle in these conditions, a number of potential targets for pharmacological interventions to reverse sarcopenia have been identified. The clinical evaluation of therapeutic candidates directed at these targets will require that the efficacy and safety of the drug candidates be adequately evaluated to meet the regulatory standards of the Food and Drug Administration (FDA). Concerns unique to drug development may require different approaches to clinical study design than have been used in the epidemiological research that identified the clinical need for these programs and the intervention trials conducted to date. In addition to being responsive to clinical need as perceived by patients and physicians, clinical trial data must demonstrate to the FDA that the drug provides an objective and clinically meaningful advantage, and must demonstrate to all involved in healthcare decision‐making that its benefits justify the associated costs and risks. Potential primary efficacy endpoints for trials of a drug for treatment of sarcopenia include physical performance, falls, fractures, and patient‐reported outcomes assessing function and quality of life. Each potential endpoint has advantages and disadvantages from scientific, clinical, and regulatory perspectives that must be carefully considered in the design of trials for sarcopenia treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1532-5415.2010.03285.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 31

Metadata

Authors
Brass, E. P., & Sietsema, K. E.
Venue
Journal of the American Geriatrics Society
Publisher
Wiley
Published
2011-03
Volume
59
Issue
3
Pages
530-535
ISSN
  • 0002-8614 (ISSN-L)
  • 1532-5415
OpenAlex
W1540752626
Cited by
31
References
4
FWCI
2.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Considerations in the Development of Drugs to Treat Sarcopenia. https://app.cochat.ai/papers/10.1111/j.1532-5415.2010.03285.x
The paper
Brass, E. P., & Sietsema, K. E. (2011). Considerations in the Development of Drugs to Treat Sarcopenia. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2010.03285.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.